Nab-paclitaxel/gemcitabine first-line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin levels: Data from the German QoliXane Pancreatic Cancer Registry.

e15739Background: Hyperbilirubinaemia is a common disease effect in patients (pts) with metastatic pancreatic cancer (mPC). As clinical trials often exclude them, data on management of these pts are rare. In the framework of a German observational multicenter study (QoliXane), quality of life and therapy data are currently being collected in pts with mPC receiving a combination of nab-paclitaxel and gemcitabine. This is an interim analysis on hyperbilirubinaemia management. Methods: Pts were included to this analysis if they entered the trial with a bilirubin level ≥ 1.5 mg/dl and completed at least 1 cycle. Bilirubin levels were documented for up to 4 cycles and methods of hyperbilirubinaemia management have been assessed. A both descriptive and explorative analysis was performed using IBM SPSS V 23. Results: 20 of 219 pts (9.1%) were included. Mean bilirubin level was 4.4 mg/dl (range 1.5-12.9) at baseline and dropped considerably by the 2nd cycle to 1.8 (range 0.35-14.1; p=0.031). Bilirubin levels decr...